Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 248

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2

Open access
Hortobagyi, Gabriel N., Chen, David, Piccart, Martine, Rugo, Hope S., Burris, Howard A., Pritchard, Kathleen I., Campone, Mario, Noguchi, Shinzaburo, Perez, Alejandra T., Deleu, Ines, Shtivelband, Mikhail, Masuda, Norikazu, Dakhil, Shaker, Anderson, Ian, Robinson, Douglas M., He, Wei, Garg, Abhishek, McDonald, E. Robert, Bitter, Hans, Huang, Alan, Taran, Tetiana, Bachelot, Thomas, Lebrun, Fabienne, Lebwohl, David, Baselga, José · 2016 · Journal of Clinical Oncology

Abstract

Purpose: To explore the genetic landscape of tumors from patients enrolled on the BOLERO-2 trial to identify potential correlations between genetic alterations and efficacy of everolimus treatment. The BOLERO-2 trial has previously demonstrated that the addition of everolimus to exemestane prolonged progression-free survival by more than twofold in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer previously treated with nonsteroidal aromatase inhibitors. Patients and Methods: Next-generation sequencing was used to analyze genetic status of cancer-related genes in 302 archival tumor specimens from patients representative of the BOLERO-2 study population. Correlations between the most common somatic alterations and degree of chromosomal instability, and treatment effect of everolimus were investigated. Results: Progression-free survival benefit with everolimus was maintained regardless of alteration status of PIK3CA, FGFR1, and CCND1 or the pathways of which they are components. However, quantitative differences in everolimus benefit were observed between patient subgroups defined by the exon-specific mutations in PIK3CA (exon 20 v 9) or by different degrees of chromosomal instability in the tumor tissues. Conclusion: The data from this exploratory analysis suggest that the efficacy of everolimus was largely independent of the most commonly altered genes or pathways in hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer. The potential impact of chromosomal instabilities and low-frequency genetic alterations on everolimus efficacy warrants further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.60.1971

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 248

Metadata

Authors
Hortobagyi, G. N., Chen, D., Piccart, M., Rugo, H. S., Burris, H. A., Pritchard, K. I., Campone, M., Noguchi, S., Perez, A. T., Deleu, I., Shtivelband, M., Masuda, N., Dakhil, S., Anderson, I., Robinson, D. M., He, W., Garg, A., McDonald, E. R., Bitter, H., Huang, A., Taran, T., Bachelot, T., Lebrun, F., Lebwohl, D., & Baselga, J.
Venue
Journal of Clinical Oncology
Published
2016-02-10
Volume
34
Issue
5
Pages
419-426
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1861759122
Cited by
248
References
5
FWCI
21.17
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2. https://app.cochat.ai/papers/10.1200/jco.2014.60.1971
The paper
Hortobagyi, G. N., Chen, D., Piccart, M., Rugo, H. S., Burris, H. A., Pritchard, K. I., Campone, M., Noguchi, S., Perez, A. T., Deleu, I., Shtivelband, M., Masuda, N., Dakhil, S., Anderson, I., Robinson, D. M., He, W., Garg, A., McDonald, E. R., Bitter, H., . . . Baselga, J. (2016). Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.60.1971

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.